Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Talpaz · SciRah

Researcher profile · Semantic Scholar

M. Talpaz

Share profile

M. Talpaz — researcher profile on SciRah

h-index: 118
Works: 854
Citations: 66K

Most-cited papers

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Michael W. Deininger, Neil P. Shah, Jessica K. Altman, E. Berman +25 more
2020The Journal of the National Comprehensive Cancer Network225 citations Open access
Semantic Scholar
Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.
J. Cortes, J. Apperley, E. Lomaia, B. Moiraghi +21 more
2021Blood185 citations Open access
Semantic Scholar
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
M. Talpaz, J. Kiladjian
2020Leukemia180 citations Open access
Semantic Scholar
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
E. Cobain, Yi-Mi Wu, P. Vats, R. Chugh +26 more
2021JAMA Oncology139 citations Open access
Semantic Scholar
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
A. Gerds, J. Gotlib, H. Ali, P. Bose +27 more
2022The Journal of the National Comprehensive Cancer Network118 citations Open access
Semantic Scholar
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
A. Gerds, M. Savona, B. Scott, M. Talpaz +22 more
2020Blood Advances91 citations Open access
Semantic Scholar
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Josh N. Vo, Yi-Mi Wu, Jeanmarie Mishler, S. Hall +19 more
2022Nature Communications87 citations Open access
Semantic Scholar
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, F. Palandri +20 more
2023Journal of Clinical Oncology72 citations Open access
Semantic Scholar
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
J. Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P. Hughes +18 more
2024Leukemia56 citations Open access
Semantic Scholar
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
M. Mauro, T. Hughes, Dong-Wook Kim, D. Réa +22 more
2023Leukemia51 citations Open access
Semantic Scholar
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
H. Kantarjian, E. Jabbour, Michael W. Deininger, E. Abruzzese +17 more
2022American journal of hematology/oncology49 citations Open access
Semantic Scholar
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
S. Verstovsek, R. Mesa, M. Talpaz, J. Kiladjian +9 more
2021Haematologica47 citations Open access
Semantic Scholar
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
E. Jabbour, J. Apperley, J. Cortes, D. Réa +16 more
2024Leukemia43 citations Open access
Semantic Scholar
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
A. Gerds, J. Gotlib, P. Bose, M. Deininger +29 more
2020The Journal of the National Comprehensive Cancer Network42 citations
Semantic Scholar
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
C. Harrison, V MNSSVKR GUPTA, A. Gerds, R. Rampal +21 more
2022Future Oncology40 citations Open access
Semantic Scholar
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
C. Harrison, N. Schaap, A. Vannucchi, J. Kiladjian +8 more
2022British Journal of Haematology29 citations Open access
Semantic Scholar
Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
R. Rampal, S. Grosicki, Dominik Chraniuk, E. Abruzzese +21 more
2023Blood27 citations
Semantic Scholar
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
J. Mascarenhas, A. Migliaccio, H. Kosiorek, R. Bhave +30 more
2023Clinical Cancer Research25 citations Open access
Semantic Scholar
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
H. Gill, A. Yacoub, K. Pettit, T. Bradley +21 more
2021Blood22 citations Open access
Semantic Scholar
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
M. Kremyanskaya, J. Mascarenhas, F. Palandri, A. Vannucchi +20 more
2021Blood20 citations Open access
Semantic Scholar
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study.
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, C. Harrison +18 more
2022Clinical Lymphoma, Myeloma & Leukemia18 citations
Semantic Scholar
Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
J. Magenau, Daniel Peltier, M. Riwes, A. Pawarode +9 more
2021Blood Advances18 citations Open access
Semantic Scholar
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
C. Harrison, N. Schaap, A. Vannucchi, J. Kiladjian +14 more
2021HemaSphere16 citations Open access
Semantic Scholar
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
K. Pettit, H. Gill, A. Yacoub, T. Bradley +28 more
2022Blood14 citations Open access
Semantic Scholar
Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
V MNSSVKR GUPTA, A. Yacoub, S. Verstovsek, R. Mesa +13 more
2022Blood13 citations Open access
Semantic Scholar
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
H. Gill, F. Palandri, D. Ross, T. Cochrane +21 more
2022Blood13 citations Open access
Semantic Scholar
Multiparametric MRI to quantify disease and treatment response in mice with myeloproliferative neoplasms
Tanner H. Robison, Manisha Solipuram, K. Heist, Ghoncheh Amouzandeh +12 more
2022JCI Insight13 citations Open access
Semantic Scholar
Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
V. Gupta, A. Yacoub, S. Verstovsek, R. Mesa +13 more
2021Blood13 citations Open access
Semantic Scholar
Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma
H. Potu, Malathi Kandarpa, L. Peterson, Alison B. Durham +2 more
2021OncoTarget13 citations Open access
Semantic Scholar
Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
J. Mascarenhas, H. Kosiorek, R. Bhave, J. Palmer +27 more
2021Blood13 citations
Semantic Scholar
P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
J. Apperley, H. Kantarjian, M. Deininger, E. Abruzzese +17 more
2022HemaSphere12 citations Open access
Semantic Scholar
Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
C. Harrison, M. Kremyanskaya, P. Bose, V MNSSVKR GUPTA +12 more
2022Blood12 citations
Semantic Scholar
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.
M. Talpaz, J. Prchal, L. Afrin, M. Arcasoy +5 more
2021Clinical Lymphoma, Myeloma & Leukemia12 citations Open access
Semantic Scholar
P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)
F. Palandri, D. Ross, T. Cochrane, C. Tate +24 more
2021HemaSphere12 citations Open access
Semantic Scholar
Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers
Arunkumar Venkatesan, J. Geng, Malathi Kandarpa, Sanjeeva J. Wijeyesakere +4 more
2021Journal of Cell Biology12 citations Open access
Semantic Scholar
Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors.
J. Shaya, K. Pettit, Malathi Kandarpa, D. Bixby +2 more
2021Clinical Lymphoma, Myeloma & Leukemia12 citations Open access
Semantic Scholar
Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
Jorge E. Cortes, M. Deininger, E. Lomaia, B. Moiraghi +17 more
2023Blood11 citations Open access
Semantic Scholar
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
V MNSSVKR GUPTA, J. Mascarenhas, M. Kremyanskaya, R. Rampal +7 more
2023Blood Advances11 citations Open access
Semantic Scholar
Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
Jorge E. Cortes, M. Deininger, E. Lomaia, B. Moiraghi +18 more
2022Blood11 citations Open access
Semantic Scholar
Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML
J. Cortes, J. Apperley, A. Hochhaus, M. Mauro +15 more
202010 citations Open access
Semantic Scholar
P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS
H. Gill, A. Yacoub, K. Pettit, T. Bradley +32 more
2022HemaSphere9 citations Open access
Semantic Scholar
The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.
T. Phillips, A. Danilov, D. Bond, A. Herrera +9 more
20219 citations Open access
Semantic Scholar
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Onima Chowdhury, J. O'Sullivan, Nikolaos Barkas, Guan-Lin Wang +77 more
2020Leukemia9 citations Open access
Semantic Scholar
Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study
C. Harrison, R. Mesa, M. Talpaz, H. Al-Ali +13 more
2023Blood8 citations Open access
Semantic Scholar
Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials
D. Peehl, C. Badea, T. Chenevert, H. Daldrup-Link +21 more
2023Tomography8 citations Open access
Semantic Scholar
BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
D. Lavie, V. Ribrag, Michael Loschi, C. Yannakou +27 more
2023Blood8 citations Open access
Semantic Scholar
Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data
S. Verstovsek, M. Salama, J. Mascarenhas, M. Talpaz +18 more
2021Blood8 citations Open access
Semantic Scholar
A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis
N. Pemmaraju, V. Gupta, H. Ali, A. Yacoub +13 more
2020Blood8 citations Open access
Semantic Scholar
P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
T. Hughes, Jordi Cortés, D. Réa, M. Mauro +17 more
2022HemaSphere7 citations Open access
Semantic Scholar
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
R. Mesa, N. Schaap, A. Vannucchi, J. Kiladjian +11 more
2021HemaSphere7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Vannucchi×21
Invite
A. Vannucchi — researcher profile on SciRah
C. Harrison×18
Invite
C. Harrison — researcher profile on SciRah
J. Kiladjian×17
Invite
J. Kiladjian — researcher profile on SciRah
S. Verstovsek×15
Invite
S. Verstovsek — researcher profile on SciRah

×13

Invite

R. Rampal — researcher profile on SciRah

J. Mascarenhas×12

Invite

J. Mascarenhas — researcher profile on SciRah

F. Palandri×10

Invite

F. Palandri — researcher profile on SciRah

Invite

A. Yacoub — researcher profile on SciRah

F. Passamonti×9

Invite

F. Passamonti — researcher profile on SciRah

Invite

R. Mesa — researcher profile on SciRah

Invite

K. Pettit — researcher profile on SciRah

Invite

A. Hochhaus — researcher profile on SciRah